M.d. Anderson Cancer Center

This phase 2 trial tested repotrectinib with or without fulvestrant in people with a rare, hormone-positive, HER2-negative metastatic breast cancer called invasive lobular carcinoma. The goal was to see if the combination could control the disease after standard treatments had st…

This early-phase trial tested radiation therapy in 36 patients with liver cancer (hepatocellular carcinoma, cholangiocarcinoma, or liver metastases) who also had impaired liver function due to cirrhosis, chemotherapy, or surgery. The goal was to find the safest dose and see if it…

This study tested the drug ofatumumab (Arzerra) in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who still had signs of disease after chemotherapy. The goal was to see if the drug could clear remaining cancer cells and keep the disease under c…

This phase 2 trial tested a combination of three drugs—ponatinib, venetoclax, and mini-hyper CVD chemotherapy—in people with relapsed or refractory T-cell acute lymphoblastic leukemia. The goal was to see if the combo could improve remission rates. However, the study was terminat…

This phase 2 trial tested the drug pembrolizumab given after radiation therapy for people with stage IVB anaplastic thyroid cancer, a rare and aggressive cancer. Only 6 participants were enrolled before the study was stopped early. The goal was to see if the combination could del…

This early-phase trial aimed to test the safety of combining two targeted drugs, adagrasib and olaparib, in people with advanced solid tumors that have a specific KRAS G12C mutation. The study planned to include patients with gynecological, breast, pancreatic, and certain lung ca…

This phase II trial tested the drug poziotinib in 93 people with advanced non-small cell lung cancer that has specific changes in the EGFR or HER2 genes. The goal was to see if the drug could shrink tumors or stop them from growing. The study was terminated early, so results are …

This study tested a combination of two drugs, copanlisib and fulvestrant, in people with advanced hormone receptor-positive (ER+ and/or PR+) cancers of the ovary, endometrium, or breast that also have certain genetic changes (PI3K/PTEN). Only 7 people took part before the study w…

This early-stage study tested a new drug combination (MGN1703 plus ipilimumab) in people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find the safest dose of MGN1703 when given with ipilimumab. The study was stopped early, bu…

This early-phase study tested a drug called plinabulin combined with radiation and immunotherapy in 19 people with advanced cancers (like lung, bladder, or melanoma) that had stopped responding to standard immunotherapy. The goal was to see if the combination was safe and could s…

This early-stage study tested the safety and best dose of combining the drugs RAD001 and docetaxel in 15 people with metastatic breast cancer. The goal was to find a dose that is tolerable while potentially controlling the disease. The study was terminated early, so results are l…

This study tested whether giving patients their own immune cells (called lymphocytes) after chemotherapy and radiation could help their immune system recover faster. It included 19 adults with lung or esophageal cancer. The treatment was designed to reduce a common side effect of…

This study tested whether two drugs, daratumumab and pomalidomide, could help control multiple myeloma that came back after a stem cell transplant. It involved 13 adults whose cancer had relapsed. The goal was to see if the combination could lead to complete remission and delay t…

This study tested a combination of two drugs, futibatinib and pembrolizumab, in people with a specific type of advanced endometrial cancer that had spread and was not responding to standard treatments. The goal was to see if the combination could shrink tumors and provide lasting…

This study looked at adding two immunotherapy drugs (ipilimumab and nivolumab) to standard radiation for people with advanced HPV-positive throat cancer. The goal was to see if the combination was safe and could shrink tumors better than radiation alone. The trial enrolled 37 par…

This phase 2 trial tested the drug erdafitinib in 11 men with castration-resistant prostate cancer that had spread to the bone. The study aimed to see if erdafitinib could slow cancer growth by blocking certain enzymes. Researchers also collected blood and bone marrow samples to …

This small early-phase trial tested whether adding pirtobrutinib to venetoclax could wipe out leftover cancer cells in people with CLL/SLL who still had detectable disease after venetoclax alone. Only 3 people enrolled before the study was terminated, so we cannot draw any reliab…

This phase II trial tested a combination of two drugs, venetoclax and decitabine, in 235 patients with certain blood cancers like acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) that had come back or not responded to treatment, as well as in older patien…

This phase II trial tested adding asciminib (ABL001) to standard tyrosine kinase inhibitor therapy in 7 people with chronic myeloid leukemia who still had traces of cancer. The goal was to see if the combination could eliminate remaining cancer cells. The study was terminated ear…

This phase 2 trial tested a combination of nab-paclitaxel (a chemotherapy) and alpelisib (a targeted drug) in people with triple-negative breast cancer that has specific genetic changes (PIK3CA or PTEN) and did not respond to standard chemotherapy. The goal was to see if the comb…

This early-phase trial tested the drug pomalidomide in 15 people with Waldenstrom macroglobulinemia, a rare blood cancer that had either come back or stopped responding to prior treatments. The main goal was to find the safest dose and watch for side effects. The study was termin…

This early-phase study tested combinations of drugs (bevacizumab, temsirolimus, valproic acid, or cetuximab) in 154 adults with advanced cancers or certain non-cancerous diseases that are hard to treat. The main goal was to find the safest doses and look for side effects. The tri…

This early-stage study tested the drug belantamab mafodotin (Blenrep) as a maintenance therapy to prevent multiple myeloma from returning after a stem cell transplant. Only 6 people took part before the study was stopped early. The main goals were to check safety and pain levels,…

This study tested a combination of three drugs (magrolimab, azacitidine, and venetoclax) in 110 adults with acute myeloid leukemia (AML) that had come back or not responded to prior treatment. The goal was to find the best dose and see how well the drugs worked together to contro…

This study tested a new way to deliver radiation therapy for central lung tumors using MRI guidance. The goal was to see if it is safe and can control tumors better than standard CT-guided radiation. Only 3 people took part before the study was stopped early.

This study tested a combination of two drugs, venetoclax and azacitidine, in 34 adults with high-risk blood cancers (MDS or CMML) that returned or didn't respond to earlier treatment. The goal was to find the safest dose and see if the combo could shrink or control the cancer. Th…

This study tested a combination of two drugs, apalutamide and abiraterone, along with prednisone, in men whose prostate cancer had spread and stopped responding to standard hormone therapy. The goal was to see if this combination could slow cancer growth. Only 7 men took part bef…

This study tested a combination of two drugs, bintrafusp alfa and pimasertib, in people whose cancer had spread to the brain. The goal was to find the safest dose and see if the treatment could slow or stop the cancer from growing. The trial was stopped early after enrolling only…

This study tested whether adding the targeted drug inotuzumab ozogamicin before and after a stem cell transplant could help control leukemia and lymphoma. It included 15 people aged 12 to 75 with certain blood cancers. The study was stopped early, but researchers looked at safety…

This study tested a new drug combination for people with metastatic melanoma (skin cancer that has spread). The goal was to find a safe dose of an experimental drug (APX005M) injected directly into tumors, combined with an approved immunotherapy (pembrolizumab) given through the …

This study tested a new drug (BMS-986218) plus nivolumab and targeted radiation in people with advanced solid tumors that had spread. The goal was to see if this combination could help the immune system fight cancer better. Only 13 people took part before the study was stopped ea…

This study looked at whether removing liver tumors with surgery, along with chemotherapy, helps people with colorectal cancer that has spread to the liver and lungs live longer compared to chemotherapy alone. The trial was stopped early after enrolling only 29 participants. The r…

This early-phase study tested a treatment using donated natural killer (NK) cells from cord blood, combined with chemotherapy, for children and young adults with solid tumors that returned or didn't respond to standard care. The goal was to find the safest dose and check for side…

This study tested two immunotherapy drugs, nivolumab and ipilimumab, in 10 people with a rare and aggressive kidney cancer called renal medullary carcinoma. The goal was to see if the combination could shrink tumors or stop them from growing. The trial was stopped early, but the …

This study looked at whether a less invasive surgery (conservative surgery) could safely treat women with early-stage, low-risk cervical cancer. The goal was to see if this approach causes fewer side effects and helps recovery. The study included 137 women with stage IA2 or IB1 c…

This early-phase trial tested whether adding the experimental drug YL-13027 to standard chemotherapy (gemcitabine and nab-paclitaxel) is safe for people with advanced pancreatic cancer that no longer responds to treatment. Only 4 participants were enrolled before the study was st…

This study tested a new treatment for head and neck cancer that has come back or spread. It combined a drug called NBTXR3 (activated by radiation) with the immunotherapy pembrolizumab. The goal was to see if this combination could shrink tumors and help patients live longer. The …

This study tested a drug called vibecotamab in adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) whose cancer did not respond to or came back after standard treatments. The drug is a special antibody designed to help the immune system attack cancer cells.…

This study tested a mix of targeted drugs (neratinib, pertuzumab, trastuzumab) and chemotherapy (paclitaxel) in people with advanced or inflammatory breast cancer. The goal was to find the best dose and see if the combination could shrink tumors before more chemo. The study was s…

This study tested a combination of the experimental drug magrolimab with cetuximab and either pembrolizumab or docetaxel in people with head and neck cancer that had come back or spread. Only 4 people enrolled before the trial was stopped early. The goal was to see if the combo c…

This early-stage study tested the safety of a drug called itacitinib in 8 adults who developed bronchiolitis obliterans syndrome (a type of lung scarring) after receiving a stem cell transplant from a donor. The goal was to see if the drug could help control the lung disease by b…

This study tested a combination of two drugs, venetoclax and azacitidine, for people with a high-risk type of bone marrow cancer called myelodysplastic syndrome (MDS) that either came back or didn't respond to treatment. The goal was to find the best dose and see how well it work…

This study tested the drug ponatinib in 51 adults with a fast-growing form of chronic myeloid leukemia (CML) who had little or no prior treatment. The goal was to see if ponatinib could control the disease by blocking a protein that drives leukemia growth. However, the drug can c…

This study looked at adding a targeted drug called venetoclax to low-intensity chemotherapy for adults with acute lymphoblastic leukemia (ALL) that came back or didn't respond to treatment. The goal was to find the safest dose and see if the combination could help control the dis…

This study tested a drug called ADCT-602 in 37 people with a type of blood cancer (B-cell acute lymphoblastic leukemia) that had returned or stopped responding to other treatments. The drug is a lab-made antibody that targets a protein (CD22) on cancer cells to stop them from gro…

This study tested whether combining two drugs, CB-103 and venetoclax, could help control T-cell acute lymphoblastic leukemia (T-ALL) in teens and young adults whose cancer had come back or not responded to treatment. Only 2 people enrolled before the trial was stopped early. The …

This study tested a combination of two drugs, omacetaxine and venetoclax, in 24 adults with relapsed or treatment-resistant acute myeloid leukemia or myelodysplastic syndrome that had a specific genetic change called RUNX1. The goal was to find the best dose and see if the combo …

This study tested a combination of two drugs, sitravatinib and nivolumab, in people with advanced kidney cancer that had spread and worsened after prior treatment. The goal was to see if the combination could shrink tumors or slow the disease. The study was stopped early after en…

This early-phase study tested whether special PET scans using glutamine and FSPG can better detect tumors in people with advanced colorectal cancer. Six participants received these imaging agents, and researchers compared the results to standard CT or MRI scans. The study was ter…

This study tested whether a combination of levocarnitine (an amino acid) and vitamin B complex could help lower high bilirubin levels caused by certain leukemia drugs. Ten adults with acute lymphoblastic leukemia who had elevated bilirubin after treatment with PEG-asparaginase or…

This very early study aimed to compare an oral (pill) version of the chemotherapy drug cladribine with the standard IV (vein) version in people with certain leukemias. Only 3 people took part before the study was stopped early. The main goal was to see how the body handles the or…

This study aimed to gather information from about 500 people with penile cancer to better understand the disease, its risk factors, treatments, and outcomes. Researchers did not provide any new treatment or intervention. The study was stopped early, but the data collected may hel…

This study looked at the quality of life of women who were pregnant while being treated for breast cancer. Researchers asked participants to fill out questionnaires about their well-being. The goal was to understand the long-term effects of this unique situation.

This study looked at whether repeated MRI scans and blood tests can predict changes in thinking and memory after brain radiation. Nine adults with brain tumors who were scheduled for radiation took part. Researchers hoped to find better ways to monitor and adjust treatment, but t…

This study looked at whether a simple finger device (Vendys II) can measure blood vessel health in children and young adults (ages 6-26) getting a stem cell transplant. The device works by briefly stopping blood flow and then tracking how the finger warms back up. The study was s…

This study aimed to help low-income pregnant women stop smoking and make their homes smoke-free. Smoking during pregnancy raises the risk of cancer and can lead to low birth weight and other health problems for the baby. The program offered support and referrals to services durin…